BCL2L1 and colorectal carcinoma: Moreover, we proved that, whereas both fibroblasts and CRC cells responded to BCL-xL, HSP90, epigenetic inhibitor and their combinations, the bromodomain epigenetic inhibitor JQ1 selected a CD44+/LUM+ CRC cell population.